Sequence: VSRRRRRRGGRRRR
| Experiment Id | EXP002537 |
|---|---|
| Paper | Cell-Penetrating Magnetic Nanoparticles for Highly Efficient Delivery and Intracellular Imaging of s |
| Peptide | Protamine |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Approx. 15 protamine per nanoparticle |
| Rna Concentration | 5–33 nM |
| Mixing Ratio | N/P ≈10 (optimal) |
| Formulation Format | Cell-penetrating magnetic nanoparticle (CPMN) |
| Formulation Components | Fe3O4 core + PMAL polymer + protamine peptide + siRNA |
| Size Nm | 30.00 |
| Zeta Mv | 26.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | MCF-7; U251 (eGFP stable lines) |
| Animal Model | |
| Administration Route | |
| Output Type | Reporter gene knockdown |
| Output Value | >85–90% eGFP silencing at 5 nM (with magnet) |
| Output Units | |
| Output Notes | Superior silencing vs Lipofectamine and PEI in serum |
| Toxicity Notes | Low cytotoxicity compared to PEI and Lipofectamine |
| Curation Notes |